| Literature DB >> 29656924 |
Hannah E Mischo1, Yujin Chun2, Kevin M Harlen3, Brendan M Smalec3, Somdutta Dhir4, L Stirling Churchman3, Stephen Buratowski5.
Abstract
Many non-coding transcripts (ncRNA) generated by RNA polymerase II in S. cerevisiae are terminated by the Nrd1-Nab3-Sen1 complex. However, Sen1 helicase levels are surprisingly low compared with Nrd1 and Nab3, raising questions regarding how ncRNA can be terminated in an efficient and timely manner. We show that Sen1 levels increase during the S and G2 phases of the cell cycle, leading to increased termination activity of NNS. Overexpression of Sen1 or failure to modulate its abundance by ubiquitin-proteasome-mediated degradation greatly decreases cell fitness. Sen1 toxicity is suppressed by mutations in other termination factors, and NET-seq analysis shows that its overexpression leads to a decrease in ncRNA production and altered mRNA termination. We conclude that Sen1 levels are carefully regulated to prevent aberrant termination. We suggest that ncRNA levels and coding gene transcription termination are modulated by Sen1 to fulfill critical cell cycle-specific functions.Entities:
Keywords: NNS; Nrd1-Nab3-Sen1; Sen1; cell cycle; non-coding RNA; transcription termination; ubiquitin-proteasome system
Mesh:
Substances:
Year: 2018 PMID: 29656924 PMCID: PMC5919780 DOI: 10.1016/j.molcel.2018.03.010
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970
Figure 1Sen1 Protein Levels Fluctuate throughout the Cell Cycle
(A) Cells were αF-arrested and released into the cell cycle for the indicated time (see FACS analysis, right). Levels of C-terminally tagged Sen1-Myc (9E11), Sic1, and Pgk1 were analyzed by immunoblotting (left).
(B) RNA analysis of SEN1 and sCR1. RNA was prepared from cells grown as in (A) (see FACS analysis, right), and 10 μg was separated on a 1% agarose gel for RNA blotting (left).
(C) Sen1 expression in drug-arrested cells. Cells grown in yeast extract, peptone, and dextrose (YPD) were arrested in G1 (5 μg/mL αF), S phase (200 mM hydroxyurea [HU]), or prometaphase (PM, 15 μg/mL nocodazole, see FACS analysis, right). Extract equivalent to 0.5 × 107 cells (Nrd1) or 2 × 107 cells (TBP, Sic1, Nab3, and Sen1 [antibody against the N terminus]) was analyzed by immunoblotting (left).
(D) Sen1 expression in elutriated cells. Cells grown in YPD were separated by elutriating centrifugation and analyzed by FACS. Extracts prepared from fractions with G1, S, and G2 DNA content were analyzed by immunoblotting for Sen1-Myc (9E11), TBP, and Sic1. Quantification of three independent elutriations normalized to G1 levels with SEM is shown below.
(E) RNA blot analysis of SNR13 and SNR13::TRS31 RNA. Wild-type, pcf11-9, ssu72-2, and sen1-1 cells grown in YPD at a permissive temperature (25°C), were arrested with αF or nocodazole and shifted to a non-permissive temperature (37°C) for 30 min. nrd1-102 cells were grown in YPD at 30°C before arrest with αF or nocodazole. 15 μg RNA was separated on a 1% agarose gel and analyzed by RNA blotting (left) against SNR13 to detect the mature snoRNA and the SNR13::TRS31 termination readthrough transcript (schematized above). The readthrough-to-snoRNA ratio for three to four biological replicates was normalized to the G1 value (y axis, SEM). Statistical significance of the difference between G1 and PM was calculated using Students’ t test. ∗p < 0.05, ∗∗p < 0.01.
Figure 2Sen1 Is Ubiquitylated and Degraded by the Proteasome
(A) Sen1 stability differs in G1- and PM-arrested cells. pGSen1Myc-transformed cells (bar1Δ) were grown in raffinose-containing medium and arrested with 0.15 μg/mL αF or 15 μg/mL nocodazole. Sen1-Myc expression was induced by addition of 2% galactose for 15 min, followed by transcription repression by addition of 2% glucose and translation inhibition after 1 hr by addition of 1 mg/mL CHX. Whole-cell extracts from the indicated time points were assayed for Sen1-Myc levels; quantification (average of n = 3 and SEM) is graphed below. See Figure S2A for FACS analysis.
(B) Sen1 degradation in G1 depends on proteasome function. Sen1-Myc cells (bar1Δ, pdr5Δ) were αF-arrested and treated with 1 mg/mL CHX. The culture was split in half and treated with DMSO (lanes 2–6) or 140 μM MG-132 and 20 μM MG-262 (lanes 7–10). See Figure S2B for FACS analysis. Graph: average of n = 3 with SEM.
(C) Sen1 is stabilized in the APC mutant cdc27-A. pGSen1Myc-transformed cdc27-A and CDC27 cells were αF-arrested in raffinose at 23°C and shifted to 37°C, and Sen1-Myc expression was induced with 2% galactose for 15 min, after which 2% glucose was added. CHX was added after 30 min, and residual Sen1 was analyzed as before. Graph: average of n = 3 CDC27 and n = 4 cdc27-A with SEM. See Figure S2D for FACS analysis.
(D) Sen1 is stabilized in metaphase-arrested cells. A galactose-inducible, non-cleavable Pds1 (Pds1Db1Δ) was integrated into Sen1-Myc cells. After αF arrest in raffinose, Pds1Db1Δ cells were released into galactose-containing medium, and CHX was added after 80 min., when most cells were arrested in metaphase (lanes 8–14). This was compared with Sen1-Myc wild-type cells, αF-arrested, and maintained in galactose for 80 min (lanes 1–7). Quantification (average and SEM, n = 4–5) is shown at the bottom. See Figure S2E for FACS analysis.
Figure 3A 40-aa Region within Sen1 Contributes to Its Instability in G1
(A) Schematic model of Sen1 domain organization. LeuZipper, a putative leucine zipper; NLS, nuclear localization sequence; Glc7, Glc7 binding motif.
(B) Deletion of aa 459–498 leads to Sen1 stabilization. 1 mg/mL CHX was added to αF-arrested wild-type cells (bar1Δ) transformed with pGSen1Myc variants Sen1, Sen-459-498Δ, or Sen1-KEN-A as described in Figure 2A. The 60-min time points in the center and at the right are from a separate gel. Bottom graph: n = 4–5, SEM. The asterisk denotes a Myc-responsive band possibly stemming from an internal promoter within Sen1, whose degradation is unchanged.
(C) RNA blot analysis (1% agarose) of 15 μg RNA isolated from SEN1 or sen1-1 cells transformed with vector, pGSen1Myc (Sen1), or Sen1-458-498Δ and induced with galactose for 3 hr at a permissive temperature prior to a 30-min shift to a non-permissive temperature. RNA blots were probed against SNR13 or NRD1 (top). Bottom: quantification normalized to sen1-1 vector readthrough (n = 3, SEM).
(D) Plasmid shuffle assay to test for the ability of query constructs to support viability. A centromeric URA3 plasmid carrying SEN1 (pRS416 ± 700Sen1) maintains the viability of a sen1Δ strain. Transformation with a query plasmid (vector, Sen1, Sen1-459-498Δ, or Sen1-D1-KEN-D2-A) and selection against the URA3 plasmid (with 5-fluorouracil [5-FOA]) leaves the query plasmid to complement the loss of SEN1. Five-fold serial dilutions. Selection medium: W, tryptophan; L, leucine; U, uracil.
Figure 4Sen1 High Copy Expression Is Toxic
(A) Sen1 expression from the multi-copy pGSen1Myc plasmid in SEN1 and sen1-1 cells. 5-fold serial dilutions were grown on selective medium with either glucose (repressing) or galactose (inducing) as the carbon source at 25°C (permissive temperature) or 37°C (non-permissive temperature).
(B) RNA blot analysis of SNR13. RNA was extracted from SEN1 or sen1-1 cells transformed with vector or pGSen1Myc. Cells were grown at 25°C in raffinose, expression was induced for 3 hr with 2% galactose or repressed with 2% glucose, and cells were shifted to a non-permissive temperature for 30 min. 20 μg RNA was separated on a 1% agarose gel, and the RNA blot was probed against SNR13.
(Ci) Sequestration model. Sen1-interacting proteins are titrated away from other cellular functions (function A).
(Cii) Excess activity model. Cells with elevated Sen1 die because transcription termination occurs prematurely. Transcription termination mutants tolerate elevated Sen1 levels by shifting the termination window back closer to the wild-type termination site.
(D) Serial 5-fold dilutions of several termination factor mutants transformed with vector or pGSen1Myc.
(E) Summary of phenotypes associated with Sen1 high copy expression in various termination mutants. +, yes; −, no; NA, non-applicable.
(F) Immunoblot of samples taken from Pcf11-hemagglutinin (HA) wild-type cells transformed with vector or pGSen1Myc and induced for the indicated times with 2% galactose.
Figure 5Sen1 High Copy Expression Suppresses Termination Defects in APT Mutants
(A) Serial 5-fold dilutions of wild-type, ref2Δ, or pta1-1 cells transformed with vector, pGSen1Myc, or two catalytically inactive point mutants of Sen1 in the Walker A and B motifs (pGSM-K1363A and pGSM-D1590A).
(B) Immunoblot analysis of whole-cell extracts from cells induced with 2% galactose to express the indicated constructs. Because of different growth rates, the induction time was varied for the wild-type-ref2Δ (6 hr) and the wild-type-pta1-1 (13 hr) pair.
(C) RNA blot analysis of SNR33 in REF2 or ref2Δ cells. 20 μg RNA was separated on a 1% agarose gel and normalized to the SNR33::YCR015c/SNR33 signal in the ref2Δ vector samples.
(D) RNA blot analysis of SNR33 in PTA1 or pta1-1 cells, performed as in (C).
Figure 6Summary of NET-Seq Results
Shown is a NETseq analysis of cells that were asynchronous, αF- or nocodazole-arrested, or induced with 2% galactose for 3 hr to express vector or pGSen1Myc (Sen1).
(A) NET-seq values in reads per million (RPM) of two biological repeats for coding mRNA (gray, rep1 n = 6554, rep2 n = 6601), CUTs (blue, n = 922 and 925), and SUTs (red, n = 835 and 843) in Sen1 or vector, represented as scatterplots. Right: cumulative distribution of the fold decrease in expression for coding genes, CUTs, and SUTs after Sen1 induction.
(B) Genome browser view (igv; http://software.broadinstitute.org/software/igv/) for individual examples depicting lower Pol II reads in Sen1 samples: YER145c, CUT116, and SUT803 (based on rep1).
(C) RPM values for coding genes (rep1 n = 6,539, rep2,3 n = 6,620), CUTs (n = 924), and SUTs (rep1 n = 834, rep2,3 n = 845) in G1-arrested versus asynchronous cells, depicted as scatterplot.
(D) Scatterplots of fold changes comparing Sen1/vector with G1/asynchronous. Shown are coding genes (gray), CUTs (blue), and SUTs (red). Among coding genes that are lower-expressed in G1 and Sen1 cells, essential genes (p = 2.2 × 10−16) and NNS-terminated genes (p = 0.043, Fisher’s exact test) are significantly overrepresented (based on rep1).
Figure 7Sen1 Affects Pol II Pausing and Termination Position
(A) Aggregate plot of all CUTs with a reads per kilobase of transcript per million mapped reads (RPKM) > 10 (n = 925) anchored at the transcription start site (TSS, i) or the annotated transcription end site (TES, ii). The shadow denotes a 95% confidence interval.
(B) Heatmap of NET-seq reads (RPM) for all CUTs in vector, Sen1 (pGSen1Myc), asynchronous, and G1-arrested cells.
(C) Aggregate plot of all coding genes with an RPKM > 10 and more than 1,000 nt (n = 2792), anchored at the TSS (i) or the poly(A) site (ii); vector (black), Sen1 (green).
(Di) Ratio of Pol II pause intensity on gene bodies compared with promoter-proximal 300 bp in vector and Sen1 cells. Also see STAR Methods.
(Dii) 15 nt up and downstream of non-overlapping pause sites were searched for motif enrichment using multiple expectation maximization for motif elicitation (MEME) (Bailey et al., 2009). The identified motif occurred in both samples (vector: 563 of 1,077 pause sites, p = 2.1 × 10−639; Sen1: 708 of 1,237 identified pause sites, p = 2.7 × 10−672).
(E) Individual gene examples from vector and Sen1 samples showing SNR33, SNR13, RPS31, and RPL8A. The RPM scale in the igv plot is indicated.
(F) Boxplot for the termination ratio of the indicated samples. The termination ratio is determined by taking the ratio of reads from 100–50 nt upstream and 50–100 nt downstream of the TES site. 5,702 coding genes that show no overlap with other transcripts 100 nt downstream of the transcript isoform-sequencing (TIF)-seq end were included in the analysis. The p values represent Student’s t test.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| anti-Myc (9E11) | House production LRI | 9E11 |
| anti-Sen1 - (raised against N-terminal stretch of Sen1) | This study | |
| anti-TBP | ||
| anti-Nrd1 | ||
| anti-Nab3 (2F12) | 2F12 | |
| anti-Sic1 | kind gift from John Diffley | |
| Anti-FLAG M2 affinity gel | Sigma-Aldrich | Cat# A2220 RRID: |
| Chemicals, Peptides, and Recombinant Proteins | ||
| Alpha-Factor | House production LRI | |
| 3x FLAG Peptide | Sigma-Aldrich | Cat#F4799 |
| Cycloheximide | Sigma-Aldrich | C7698 |
| Nocodazole | Sigma-Aldrich | M1404 |
| MG-132 | MERCK | 474790 |
| MG-262 | Stratech | A8179-APE |
| Raw data deposition at Mendeley | This study | Mendeley: |
| Raw Sequencing data | This study | GEO: |
| BMA64 (MATa | (YF1342) | |
| Brr5-1 (YSN399; MATα | (HY431/YF1437) | |
| BY4741 (MATa | Euroscarf | (FY44) |
| BYSHM (MATa | This study | (HY202) |
| BYSHM Pdr5D (MATa | This study | (HY270) |
| cdc16-123 ((W303) MATa | L. Drury/J. Diffley | (FY59) |
| cdc27-A ( | A. Amon | (HY500/ YF2412) |
| Cft2-1/Ydh1Δ (MATa | (HY403/YF2367) | |
| Fip1-1 (LM94; MATα | (HY397/YF2360) | |
| Glc7-5 (MATa | (HY406/YF2369) | |
| Mpe1-1 ((W303-1B) MATα | (HY430/YF1982) | |
| Nab3-11 (YPN103; (W303-1B) MATα | (HY371/YF1471) | |
| nrd1-101 (YJC1282; BY4741 (S288C) MATa | Jeff Corden | (HY127/YF2347) |
| nrd1-102 ([nrd1 (V379G)]; (S288C) MATa | Minkyu Kim | (HY479/YSB2079) |
| Pcf11-13 ((W303, | This study | (HY312) |
| Pcf11-2 (NA65; (W303-1B) MATa | (HY366/YF1434) | |
| Pcf11-9 (NA67; (W303-1B) MATa | (HY305/YF1435) | |
| PFS2 (MO12; (W303-1B) | (HY407/YF2370) | |
| Pfs2-1 (MO17; (W303-1B) | (HY408/YF2371) | |
| Pta1-1 (P0C8-23d; MATa | (HY379/YF175) | |
| Rad2Δ ((S288C) MATa | (YF2230) | |
| Ref2Δ ((S288C) MATa | (HY361/YF1996) | |
| rnt1Δ W303) (MATa | (HY163/YF1343) | |
| Shuffle strain ((BY4743; S288C) | This study | (HY459/YSB3181) |
| Srs2Δ (BY4741 (S288C) MATa | YF2355 | |
| Ssu72-2 (MATa | (HY378/YF1374) | |
| Swd2Δ pRS414 D2 (MATa | This study | (HY446) |
| Syc1Δ ((S288C) MATa | (HY365/ YF2354) | |
| W303 RAD5+ ((W303) MATa | Andres Aguilera | (HY307/YF2329) |
| W303-1A (MATa | Andres Aguilera | (FY1) |
| W303bar1Δ ((W303) MATa | (HY115/YF2348) | |
| WF1ASHM (MATa | This study | (HY185) |
| WF1ASHM Pds1DbΔ (WF1ASHM with p258 (Pds1Δdb) integrated.) | This study | (HY509) |
| WF1B (Matα | (HY71/YF2349) | |
| WF1D (MATa | (HY73) | |
| YTH1 (YT2; MATa | (HY400/YF2364) | |
| Yth1 DC2 (YT5; MATa | (HY402/YF2366) | |
| sCR1 up (GGCTGTAATGGCTTTCTGGTG) | This study | N/A |
| sCR1 dw (CACAATGTGCGAGTAAATCCTG) | This study | N/A |
| hm331 Sen1 Pst1 3′ 6369 (CATCATCTGCAGCTCGAAGAACCAC | This study | N/A |
| SB#1309 SNR13-60 (TTATAAATGGCATCTCAAATCGTC) | This study | N/A |
| SB#1310 SNR13+124 to end (GGTCAGATAAAAGTAAAAAAA | This study | N/A |
| hm427 SNR 13 3′ SacII MboI (GTCACCGCGGGATCGGATGGT | This study | N/A |
| SB#1319 snr33 Pro-up (CGGAACGGTACATAAGAATAGAAGAG) | This study | N/A |
| SB#1322 snR33 3UTR low +288 (TAAAGAAAACGATAAGA | This study | N/A |
| hm527 Sen1Opt F2003A F (GGTAAGAAAAAGAACAACAAGCA | This study | N/A |
| hm529 Sen1Opt R302W F (CGTTGTTTCTCAATTCTGGTCTTG | This study | N/A |
| hm510 Sopt K1363A R (CGATAATACCCAAAATAGTCTTAGTG | This study | N/A |
| hm514 Sopt D1590A R (CGGTGCATTGACAAGCTTCAGCGAT | This study | N/A |
| hm472 S D1 3′ (CATTTATAATAAACAGATGCGC) | This study | N/A |
| hm492 Sopt D4 R (GGCAATAATTCTCAAGAAAGCCATG) | This study | N/A |
| hm493 Sopt D5 F 1494 (TTCGAAACTGTCTTGTTGACCAAGAC) | This study | N/A |
| hm480 D4 R 1374 IIA (GGCTATTATACGCAGGAACGCC) | This study | N/A |
| hm477 S D5 F 1494 (TTTGAAACAGTACTGTTGACTAAAAC) | This study | N/A |
| hm539 F2003A introd Pml1 (GGTAAAAAGAAAAATAACAAACA | This study | N/A |
| hm473 S D2 F 2067 (AATACATTTGACGTTGAGGGTAGAC) | This study | N/A |
| hm550 ssu72 5′ 53+ (CAACAATCGTTCAATGGAATCGC) | This study | N/A |
| hm551 ssu72 3′ 311 (CTTTCTTGCCATTTTTCAGGTGC) | This study | N/A |
| SB#1623 Nrd1 ORF0-down (CTTATGTTCAAGTTTAAAGGAGGAC) | This study | N/A |
| SB#1640 Nrd1 1aa-up(+1) (ATGCAGCAGGACGACGATTTTCAA) | This study | N/A |
| SB#3861 SEN1 - Dbox1mut R (AGTCGCCACAGCTGCCAACAAG | This study | N/A |
| SB#3856 2 SEN1 - KEN WT F (ATTAAGGAAAATGAAAGGGCAA | This study | N/A |
| SB#3860 3 SEN1 - Dbox1wt R (AGTCAACACAGCCCTCAACAA | This study | N/A |
| SB#3859 4 SEN1 - KEN-AAA+Dbox2mut F (ATTGCAGCGGCCG | This study | N/A |
| SB#3858 5 SEN1 - Dbox2mut F (ATTAAGGAAAATGAAGCGGC | This study | N/A |
| SB#3857 6 SEN1 - KEN-AAA F (ATTGCAGCGGCCGAAAGGGC | This study | N/A |
| pYMHHM | Genescript | |
| pGSen1Myc | Geneart | |
| pGSM-F2003A | This study | |
| pGSM-R302W | This study | |
| pGSM-K1363A | This study | |
| pGSM-D1590A | This study | |
| pGSen1Myc-459-498Δ | This study | |
| pRS416 +-700 Sen1 | This study | |
| pRS414 +-700 Sen1 | This study | |
| pRS414 +-700 Sen1 459-498Δ | This study | |
| pRS414 +-700 Sen1 D2 | This study | |
| pRS414 +-700 Sen1-KEN A | This study | |
| pRS414+-700 Sen1-Dbox2 A | This study | |
| pRS414+-700 Sen1-Dbox1 Dbox2 A | This study | |
| pRS414+-700 Sen1-Dbox1 KEN A | This study | |
| pRS414+-700 Sen1-KEN Dbox 2 A | This study | |
| pRS414+-700 Sen1-Dbox1 KEN Dbox 2 A | This study | |
| pRS414+-700 Sen1-Δ485-505 | This study | |
| P258 | This study | |
| TopHat2 | ||
| HTSeq package | ||
| deepTools | ||
| FIMO | ||